Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Gregory Mundy"'
Autor:
Yumei Lin, Mary A. Murray, I. Ross Garrett, Gloria E. Gutierrez, Jeffry S. Nyman, Gregory Mundy, David Fast, Kevin W. Gellenbeck, Amitabh Chandra, Shyam Ramakrishnan
Publikováno v:
Journal of Nutritional Science, Vol 3 (2014)
Using a sequential in vitro/in vivo approach, we tested the ability of botanical extracts to influence biomarkers associated with bone resorption and bone formation. Pomegranate fruit and grape seed extracts were found to exhibit anti-resorptive acti
Externí odkaz:
https://doaj.org/article/7f5dfdb75dcb45399c89660a07be172f
Autor:
Yasaman Damestani, Ruiyang Shi, Kai Li, Patrice Melikian, Shelley Haybeck, Gregory Mundy, Gursharan Gill, Shijie Tang, Eric Sbar, Tracey Duncan, Sharon Tamir, Eran Shacham, Jatin J. Shah, Sharon Shacham, Patrick Y. Wen, Erin Dunbar, Priya Kumthekar, Howard Colman, Robert Aiken, Nicholas A. Butowski
Publikováno v:
Journal of Clinical Oncology. 40:2045-2045
2045 Background: Glioblastoma (GBM) is an aggressive primary tumor with poor prognosis and survival. Patients (pts) experience debilitating symptoms that have a negative effect on quality of life (QoL). A multidisciplinary approach is necessary to fa
Autor:
Howard Colman, Frances Chow, Jatin P. Shah, Gregory Mundy, Andrew B. Lassman, Rebecca Harrison, Yasaman Damestani, Yang Liu, Vyshak Venur, Warren P. Mason, Nicholas Butowski, Minesh P. Mehta, Paul Duic, Sharon Tamir, Michael Schulder, John A. Boockvar, Kai Li, Yazmin Odia, Patrick Y. Wen, Erin M. Dunbar, Samuel Goldlust, Sharon Shacham, Scott R. Plotkin, Eric Sbar, Priya Kumthekar
Publikováno v:
Neuro Oncol
BACKGROUND Glioblastoma (GBM) is the most common and aggressive primary brain tumor with median overall survival of 15 months and 5-7 months for patients with newly diagnosed or recurrent disease (nGBM or rGBM), respectively. Selinexor is a first-in-
Autor:
Gregory Gay, Tim Menzies, Omid Jalali, Gregory Mundy, Beau Gilkerson, Martin Feather, James Kiper
Publikováno v:
Automated Software Engineering. 17:87-116
Solutions to non-linear requirements engineering problems may be "brittle"; i.e. small changes may dramatically alter solution effectiveness. Hence, it is not enough to just generate solutions to requirements problems- we must also assess solution ro
Publikováno v:
Cancer. 80:1527-1528